Stock comparison
argenx SE
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ARGX
argenx SE
Market cap
$49.91B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ARGX | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 60C | 75B | IDXX |
| Benjamin Graham | 74D | 80A | IDXX |
| Philip Fisher | 80C | 75B | ARGX |
| Peter Lynch | 71B | 71B | Tie |
| Joel Greenblatt | 57C | 83C | IDXX |
| Charlie Munger | 59D | 87A | IDXX |
| Terry Smith | 53D | 84A | IDXX |
Side-by-side metrics
| Metric | ARGX | IDXX |
|---|---|---|
| Market cap | $49.91B | $44.12B |
| P/E (TTM) | 44.1x | 39.0x |
| EV/EBIT | 44.4x | 31.6x |
| ROIC (TTM) | 11.74% | 40.66% |
| Gross margin | 89.0% | 62.05% |
| Net margin | 33.42% | 24.63% |
| Revenue CAGR 5y | 70.0% | 7.56% |
| EPS CAGR 5y | 42.58% | 10.79% |
| Debt / Equity | 0.0x | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ARGX leads on
- Debt / Equity0.0xvs 0.7x+98%
- Revenue CAGR 5y70.0%vs 7.56%+89%
- EPS CAGR 5y42.58%vs 10.79%+75%
- Gross margin89.0%vs 62.05%+30%
IDXX leads on
- ROIC (TTM)40.66%vs 11.74%+71%
- EV/EBIT31.6xvs 44.4x+29%
- P/E (TTM)39.0xvs 44.1x+12%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.